Abstract
1. Free plasma lignocaine concentrations were measured for up to 48 h after constant infusion of the drug in 41 subjects with suspected acute myocardial infarction. 2. The free plasma lignocaine clearance at 12 h was significantly and proportionately related to body weight and to the presence of mild (Killip Class II) heart failure, with an 18% reduction in free clearance in the latter condition. 3. The free plasma lignocaine was not related to sex, age or the presence of confirmed acute myocardial infarction, when corrected for the effects of body weight and presence of heart failure. 4. Free plasma lignocaine concentration 1 h after a fixed loading dose were also significantly related to body weight and presence of heart failure but not to sex, age or proven acute myocardial infarction. 5. The data indicate that correction of loading and maintenance infusion for body weight and presence of (even mild) heart failure should somewhat reduce variability in free (and presumably active) plasma lignocaine concentrations but that the free plasma lignocaine concentration at 12 h is most accurately predicted by measuring the free (and to a lesser extent total) plasma lignocaine concentration at 1 h.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Abernethy D. R., Greenblatt D. J. Impairment of lidocaine clearance in elderly male subjects. J Cardiovasc Pharmacol. 1983 Nov-Dec;5(6):1093–1096. doi: 10.1097/00005344-198311000-00027. [DOI] [PubMed] [Google Scholar]
- Barchowsky A., Shand D. G., Stargel W. W., Wagner G. S., Routledge P. A. On the role of alpha 1-acid glycoprotein in lignocaine accumulation following myocardial infarction. Br J Clin Pharmacol. 1982 Mar;13(3):411–415. doi: 10.1111/j.1365-2125.1982.tb01394.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- LeLorier J., Grenon D., Latour Y., Caillé G., Dumont G., Brosseau A., Solignac A. Pharmacokinetics of lidocaine after prolonged intravenous infusions in uncomplicated myocardial infarction. Ann Intern Med. 1977 Dec;87(6):700–706. doi: 10.7326/0003-4819-87-6-700. [DOI] [PubMed] [Google Scholar]
- Prescott L. F., Adjepon-Yamoah K. K., Talbot R. G. Impaired Lignocaine metabolism in patients with myocardial infarction and cardiac failure. Br Med J. 1976 Apr 17;1(6015):939–941. doi: 10.1136/bmj.1.6015.939. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Routledge P. A., Shand D. G., Barchowsky A., Wagner G., Stargel W. W. Relationship between alpha 1-acid glycoprotein and lidocaine disposition in myocardial infarction. Clin Pharmacol Ther. 1981 Aug;30(2):154–157. doi: 10.1038/clpt.1981.141. [DOI] [PubMed] [Google Scholar]
- Routledge P. A., Stargel W. W., Barchowsky A., Wagner G. S., Shand D. G. Control of lidocaine therapy: new perspectives. Ther Drug Monit. 1982;4(3):265–270. doi: 10.1097/00007691-198208000-00003. [DOI] [PubMed] [Google Scholar]
- Routledge P. A., Stargel W. W., Wagner G. S., Shand D. G. Increased alpha-1-acid glycoprotein and lidocaine disposition in myocardial infarction. Ann Intern Med. 1980 Nov;93(5):701–704. doi: 10.7326/0003-4819-93-5-701. [DOI] [PubMed] [Google Scholar]
- Salzer L. B., Weinrib A. B., Marina R. J., Lima J. J. A comparison of methods of lidocaine administration in patients. Clin Pharmacol Ther. 1981 May;29(5):617–624. doi: 10.1038/clpt.1981.86. [DOI] [PubMed] [Google Scholar]
- Thomson P. D., Melmon K. L., Richardson J. A., Cohn K., Steinbrunn W., Cudihee R., Rowland M. Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans. Ann Intern Med. 1973 Apr;78(4):499–508. doi: 10.7326/0003-4819-78-4-499. [DOI] [PubMed] [Google Scholar]